debt_leverage_profile
Minimal debt; largely equity-financed clinical-stage biotech with ~$50–80M cash runway; 20% rate rise has negligible direct debt cost impact
Inferred
Agent_Inference
interest_rate_sensitivity
Low direct sensitivity; no significant floating-rate debt, but higher rates increase opportunity cost of cash and raise equity dilution cost
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API synthesis reliance on European CMOs (notably France/Germany) and Chinese raw material suppliers for psychiatric drug candidates
Inferred
Agent_Inference
international_expansion_readiness
Pre-revenue clinical stage; no material international commercial revenue; sovereign currency devaluation risk is effectively zero currently
Inferred
Agent_Inference
geographic_footprint
Operations primarily US-based; clinical trials in Europe; no commercial revenue markets generating meaningful currency exposure
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CMO dependency likely exceeds 30% of operational input cost for drug manufacturing; non-substitutable on short notice given regulatory qualification requirements
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biopharma; not cloud-infrastructure-dependent for core operations; AWS/GCP termination would disrupt data management but not halt trials
Inferred
Agent_Inference
business_model_type_secondary
IP licensing and pharma partnership model; cloud disruption manageable within 60–90 days via alternative providers
Inferred
Agent_Inference
switching_cost_profile
Low API/cloud coupling risk; primary value locked in proprietary CNS drug IP, not software integrations or API dependencies
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is pharmaceutical royalties/licensing, not a security; Howey Test not applicable; low regulatory misclassification risk
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR exposure from EU clinical trial patient data; CCPA exposure minimal given no consumer-facing product; compliance frameworks standard for biopharma
Inferred
Agent_Inference
antitrust_exposure_flag
Minimal antitrust risk; single-product pipeline company with no market dominance; standard pharma patent exclusivity is legally protected
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Effectively 0% recurring commercial revenue currently; milestone and royalty payments are transactional and contingent on regulatory/commercial events
Inferred
Agent_Inference
monetization_vector
Milestone payments, licensing fees, and future royalties from CNS drug partnerships (e.g., Janssen, Ipsen collaborations)
Inferred
Agent_Inference
pricing_architecture
No commercial pricing architecture yet; future pricing will follow specialty CNS drug models (~$20K–$80K/year), subject to payer negotiation
Inferred
Agent_Inference
pricing_power_rating
Moderate-to-high potential if approved; CNS/psychiatric drugs with differentiated mechanisms command premium pricing with limited substitutes
Inferred
Agent_Inference
target_gross_margin_bracket
Expected 70–85% gross margin at commercial stage, typical for partnered specialty pharma with royalty/milestone structure
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; IP-protected drug development with no open-source or replicable substitute; churn concept not applicable pre-revenue
Inferred
Agent_Inference
headcount_cost_structure
Headcount-sublinear; asset-light model outsources manufacturing and trials to CROs/CMOs; doubling revenue via milestones requires minimal headcount increase
Inferred
Agent_Inference
marginal_cost_of_growth
Near-zero marginal cost for milestone receipts; incremental trial costs are fixed-per-study, not proportional to revenue scale
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale (commercial launch), CAC irrelevant; payer/prescriber adoption costs (medical affairs, sales force) would be primary growth cost
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; drug efficacy and prescriber adoption are independent of user base size
Inferred
Agent_Inference
asset_efficiency_ratio
-32.8% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; CNS/psychiatric drugs address serious unmet needs, but reimbursement pressure and payer scrutiny increase in downturns
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical/biotech partners (B2B licensing); currently Janssen (J&J) and Ipsen represent primary counterparties
Inferred
Agent_Inference
customer_segment_secondary
Future: psychiatrists and neurologists (prescribers) and specialty pharmacy channels for end-patient CNS drug delivery
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Minimal capex; capital deployed almost entirely into R&D and clinical trials; no legacy infrastructure reallocation required
Inferred
Agent_Inference
sec_cik
0001598646
High
SEC-EDGAR
ticker
NERV
High
SEC-EDGAR